---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125332"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:35:54.516343+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FibroGen Q3 revenue up 15% to $46.3M; net loss narrows to $17.1M; reiterates FY guidance

## Summary
- Net product revenue from roxadustat in China $46.2M, +57% YoY; total roxadustat net sales $96.6M, +25% YoY.
- Net loss $17.1M ($0.17 loss per share) vs $63.6M ($0.65) YoY; cash & equivalents $160M sufficient into 2026.
- Full-year guidance: total roxadustat net sales $330-350M; net product revenue $135-150M; cost plan substantially complete by year-end.
- Pamrevlumab trials in pancreatic cancer (mPDAC and LAPC) failed primary endpoints; pipeline focus shifts to FG-3246 ADC.
- FG-3246 Phase 2 combo study results expected 1H 2025; Phase 2 monotherapy trial starts Q1 2025; CIA approval decision early 2025.

## SEC filing metadata
- accession: 0000950170-24-125332
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/0000950170-24-125332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017024125332/fgen-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125332
- JSON: https://secwatch.observer/filing/0000950170-24-125332.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125332.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.